Last reviewed · How we verify
Lenvatinib 20mg
Lenvatinib 20mg is a Small molecule drug developed by National Cancer Center Hospital East. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lenvatinib 20mg |
|---|---|
| Sponsor | National Cancer Center Hospital East |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (PHASE3)
- Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment (PHASE2)
- A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (PHASE2)
- Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (PHASE2)
- Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma (PHASE2)
- Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenvatinib 20mg CI brief — competitive landscape report
- Lenvatinib 20mg updates RSS · CI watch RSS
- National Cancer Center Hospital East portfolio CI
Frequently asked questions about Lenvatinib 20mg
What is Lenvatinib 20mg?
Who makes Lenvatinib 20mg?
What development phase is Lenvatinib 20mg in?
Related
- Manufacturer: National Cancer Center Hospital East — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing